89bio, Inc.
ETNBNASDAQHealthcare
$14.84
+$0.00(+0.00%)
Market Cap$2.2B
P/E Ratio—
52W High$15.06
52W Low$4.16
89bio, Inc.（ETNB）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · ETNB · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.35B | $0.12B | $0.08B | $0.07B | $0.04B |
| G&A Expenses | $0.04B | $0.03B | $0.02B | $0.02B | $0.01B |
| Total Operating Expenses | $0.38B | $0.15B | $0.10B | $0.09B | $0.05B |
| Operating Income | ($0.38B) | ($0.15B) | $0.10B | ($0.09B) | ($0.05B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.37B) | ($0.14B) | ($0.10B) | ($0.09B) | ($0.05B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Net Income | ($0.37B) | ($0.14B) | ($0.10B) | ($0.09B) | ($0.05B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.51 | $-2.00 | $-2.93 | $-4.48 | $-3.08 |
| Wtd Avg Shares | 0.10B | 0.07B | 0.03B | 0.02B | 0.02B |
| EBITDA | ($0.38B) | ($0.13B) | ($0.10B) | ($0.09B) | ($0.05B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解89bio, Inc.
关于89bio, Inc.（ETNB）损益表
89bio, Inc.（ETNB）损益表数据来源于SEC Form 10-K及10-Q申报文件。2024财年，ETNB实现营收$0.00B，毛利润($0.00B)（毛利率—），净利润($0.37B)（净利率—）。
常见问题
ETNB · 4 问89bio, Inc.（ETNB）2024财年营收为$0.00B，同比down—%。
ETNB revenueETNB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08